CURRICULUM VITAE

Srinivas Vinod Saladi Ph.D.

EDUCATION

PhD: Department of Biochemistry and Cancer Biology, University of Toledo, College of Medicine (formerly Medical College of Ohio), Toledo, OH, USA (2006-2011). PI: Dr. Ivana de la Serna

MS**:** Integrated Biology, School of Biological Sciences, Madurai Kamaraj University, Madurai, Tamil Nadu, India. (2000-2002)**.** PI: Dr. G Shanmugam

BS: Biochemistry, Microbiology and Aquaculture, Nagarjuna University**,** Vijayawada, India (1997-2000).

Research and Professional Employment

2024- **Assistant Professor,** Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH

2019-2023 **Assistant Professor,** Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA, USA

2019-2023 **Associate Member,** Cancer Program, Broad Institute of Harvard and MIT

2019-2023 **Member,** Melanoma, Head and Neck Cancers & Cancer Genetics and Epigenetics, programs, Dana Farber, Harvard Cancer Center

2018- 2023 **Founding Member:** Mike Toth Head and Neck Cancer Research Center, Molecular Oncology Research Labs

2018-2023 **Assistant Scientist,** Mass. Eye and Ear Infirmary, Harvard Medical School, MA, USA

2018-2019 **Instructor,** Otolaryngology Head and Neck Surgery, Harvard Medical School, MA, USA

2017-2018 **Instructor,** MGH Cancer Center/Harvard Medical School, MA, USA

2011-2017 **Postdoctoral Research Fellow**, MGH Cancer Center/Harvard Medical School, MA, USA.

2006-2011 **Graduate Research**, University of Toledo, College of Medicine (formerly *Medical College of Ohio*), Ohio USA

2006-2006 Scientist, Drug Discovery, Jubilant Biosys, Bangalore, India

2004-2005 Project Associate, Center for Cellular and Molecular Biology, India

2003-2004 Project Associate, Weizmann Institute of Sciences, Israel.

2002-2003 Project Associate, Lab of molecular Virology, CDFD, India.

2001-2002 **Masters thesis,** Cancer Biology Unit, Madurai Kamaraj University, India.

2001-2001 Summer Research Fellowship, Lab of Bacterial Genetics, Center for DNA fingerprinting and Diagnostics (CDFD), India.

Academic and Professional Honors

2018 Awarded “Norman Knight Leadership Development Award”

2018 Won “Poster of Distinction” at the annual MGH Scientific Advisory Committee meeting

2017 Awarded “Douglass Family Foundation Prize for Excellency in Hematology-Oncology Laboratory Research” by Massachusetts General Hospital, Cancer Center.

2016 Won the Faculty of 1000 (F1000) best presentation award at the 7th International p63/p73 Workshop held at Boston.

2015 Selected for Oral presentation at the “Mechanism and Models of Cancer” meeting at Salk Institute.

2011 Invited to give commencement speech for the 2011 University of Toledo, College of Medicine, Graduation Commencement Ceremony.

2011 Received Dean’s Award for Outstanding Graduating Ph.D. student, University of Toledo, College of Medicine (formerly Medical College of Ohio).

2011 Abstract accepted for “Late-Breaking Research” session at the AACR 102nd annual Meeting.

2010 Received Travel award for attending the “Mechanisms & Models of Cancer” meeting at Cold Spring Harbor Laboratory (CSHL).
2001 Selected for Summer Fellowship at CDFD, India (1 of 20 students selected nationwide)

Organizational Activities

2022-2023 Mentor, Joint Mentorship Program for the Harvard Post Doc Association, Harvard Medical School and affiliated hospitals
2022- Member, Research Advisory Council, P.B. Siddhartha College of Arts and Science, Siddhartha Academy, India
2022-2023 Adhoc reviewer for grants, Florida Department of Health Biomedical Research Program.
2022-2023 Member, Research Steering Committee for the Otolaryngology Head and Neck Surgery departments at Harvard Medical School
2022 Panelist, SUCCrEED panel discussion on Transition to Academic position, MGH Center for Cancer Research. Feb 1st, 2022
2021-2023 Committee Member for “Basic and Translational Service", American Head and Neck Society
2021 Early Career Reviewer, Tumor Micro-Environment study section, NIH
2020-2023 Mentor, Mentor-Mentee committee for transition to Academic faculty positions, Mass. General Hospital Postdoc Association
2020-2023 Member, Institute Biosafety Committee, Massachusetts General Brigham Hospitals
2020 Panelist for Academic Career at Cold Spring Harbor Laboratory Meeting, on “Finding the Right Postdoc and Applying for Faculty Positions”
2018 Panelist for Academic Career at Cold Spring Harbor Laboratory Meeting, on “Finding the Right Postdoc”
2016-2017 Co-Chair, Academic Committee, Massachusetts General Post-Doctoral Association (MGPA).
2013 Member of Young Investigator Meeting organization, Boston, held Sep 27-29.

Editorial Activities/Adhoc Reviewer

2023- *Genome Medicine, Cell Reports, iScience, PNAS*
2022- NAR *Cancer, FASEB, Cancer Communications*
2020- *Nature Communications, JCI Insight*
2019- *Oral Oncology, Molecular Cancer*
2018- *PeerJ, FEBS J, Molecular Cancer, Journal of Translational Medicine, European Journal of Pharmacology, Frontiers in Cell and Developmental Biology (Associate Editor)*
2015- *BMC Genomics, Cancer Letters*
2014- *PLOS One (Editor: 2018-)*, F1000
2014 PhD thesis examiner for Deakin University, Australia

PEER-REVIEWED PUBLICATIONS

1. Gobbi G, Grieco A, Torricelli F, Sauta E, Santandrea G, Zanetti E, et al, **Saladi SV**, Ambrosetti DC, Ciarrocchi A, Sancisi V. The long non-coding RNA TAZ-AS202 promotes lung cancer progression via stabilization of the E2F1 transcription factor and activation of Ephrin signaling. Cell Death and Disease. 2023 Nov 18;14(11):752
2. Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, et al, **Saladi SV**, Wheeler D, Arvanitis L, Massarelli E, Kulkarni P, Zeng Y, Salgia R. Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. iScience. 2023 Jul 10;26(8):107302
3. Quan Y, Wei W, Ergin V, Rameshbabu AP, Huang M, Tian CJ, **Saladi SV**, Indzhykulian AA, Chen Z. Reprogramming by Drug-like Molecules Leads to Regeneration of Cochlear Hair Cell-like Cells in Adult Mice. PNAS. 2023. Apr 25;120(17):e2215253120.
4. Chen N, Vohra M, **Saladi SV**. Protocol for Bulk-ATAC sequencing in Head and Neck squamous cell carcinoma. STAR Protocols. 2023. Apr 17;4(2):102233.
5. Ranganath K, Feng AL, Franco RA, Varvares MA, Faquin WC, Naunheim MR, **Saladi SV.** Molecular Biomarkers of Malignant Transformation in Head and Neck Dysplasia. Cancers (Basel). 2022 Nov 15;14(22):5581.

6. Chen N, Gabriel G, Ghose S, Lin B, Langenbucher A, Webb J, Bhanot H, Abt NB, Lin D, Varvares M, Sattler M, Elgoff AM, Joh R, Uppaluri R, Emerick KS, Lawrence MS, **Saladi SV**. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promote tumorigenesis through cooperation with BRD4. Cell Reports. 2022 June;39(11):11970-83.
7. Park JC, Krishnakumar HN, **Saladi SV**. Current and future biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma. Current Oncology. 2022 June;(29) 4185-4199.
8. Pal R, Hom ME, van den Berg NS, Lwin TM, Lee YJ, Prilutskiy A, Faquin W, Yang E, **Saladi SV**, Varvares M, Rosenthal EL, Kumar ATN. First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes. Clin Cancer Res. 2022 Jun 1;28(11):2373-2384.
9. Lapidot M, **Saladi SV,** Salgia R, Sattler M. Novel therapeutic targets and immune dysfunction in malignant pleural mesothelioma. Front. Pharmacol. 2021 Dec 16. doi: 10.3389/fphar.2021.806570.
10. Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, **Saladi SV**, Ramaswamy S, Lawrence MS, Ellisen LW. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Jun 24. doi: 10.1158/1078-0432.
11. Lapidot M, Case AE, Weisberg EL, Meng C, Walker SR, Garg S, Ni W, Podar K, Hung YP, Carrasco RD, Knott A, Gokhale PC, Sharma S, Pozhitkov A, Kulkarni P, Frank DA, Salgia R, Griffin JD, **Saladi SV**, Bueno R, Sattler M. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 Jun 4. doi: 10.1038/s41416-021-01441-7
12. Choi JE, Sebastian C, Ferrer CM, Lewis CA, Sade-Feldman M, LaSalle T, Gonye A, Lopez BGC, Abdelmoula WM, Regan MS, Cetinbas M, Pascual G, Wojtkiewicz GR, Silveira GG, Boon R, Ross KN, Tirosh I, **Saladi SV**, Ellisen LW, Sadreyev RI, Benitah SA, Agar NYR, Hacohen N, Mostoslavsky R. A unique set of glycolytic tumor-propagating cells drive squamous cell carcinoma. Nature Metabolism. 2021 Feb;3(2):182-195.
13. Lapidot M, Case AE, Larios D, Gandler HI, Meng C, Tošic I, Weisberg EL, Poitras MJ, Gokhale PC, Paweletz CP, Podar K, Salgia R, **Saladi SV**, Griffin JD, Frank DA, Bueno R, Sattler M. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1).
14. Lin DT*, Lin B*, Bhanot H, Riou R, Abt NB, Rajagopal J, **Saladi SV**. RUVBL1 is an amplified epigenetic factor promoting proliferation and inhibiting differentiation program in head and neck squamous cancers. Oral Oncology 2020; (111):104930.
15. Karaayvaz M, Silberman R[*], Langenbucher A[*], **Saladi SV**[*], Ross K, Zarcaro E, Desmond A, Yildirim M, Vivekanandan V, Ravichandran H, Mylavagnanam R, Specht M, Ramaswamy S, Lawrence M, Amon A, Ellisen LW. Aneuploidy and deregulated DNA damage response define haploinsufficiency in breast tissues of BRCA2 mutation carriers. Science Advances, 2020 Jan 29;6(5):eaaay2611.
(* denotes equal contribution)
16. Aras S, **Saladi SV,** Basuroy T, Marathe HG, Lores P, de la Serna IL, Baf60a mediates interactions between MITF and the BRG1 containing SWI/SNF complex during differentiation. Journal of Cellular Physiology 2019;234(7):11780-11791.
17. Tata PR*, Chow RD*, **Saladi SV**, Tata A, Konkimalla A, Bara A, Montoro D, Hariri LP, Shih A, Mino-Kenudson M, Mou H, Kimura S, Ellisen LW, Rajagopal J. Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. Dev Cell 2018; (44):679-93.
18. Matissek KJ*, Onozato ML*, Sun S*, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, **Saladi SV**, Macleay A, et al. Clinical Genotyping Reveals Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor Positive Breast Cancer. Cancer Discovery 2018; (3):336-53
    - Article featured as cover of the issue.
    - Article previewed in the issue highlighting the significance of the study.
19. **Saladi SV,** Ross K, Karaayvaz M, Tata PR, Hongmei M, Rajagopal J, Ramawamy S, Ellisen LW. ACTL6A is co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation and Poor Prognosis. Cancer Cell. 2017; (31):35-49.
    - Article cited as Breaking Advances: Highlights from recent cancer literature by Cancer Research. 2017; **77**:1507-1508

20. **Saladi SV,** Ellisen LW. Oral Cancer. Genomics, Personalized Medicine and Oral Disease. Springer Edition 2015; 293-309.
21. Mehrotra, A, **Saladi SV**, Trivedi, AR, Aras, S, Qi, H, Jayanthy, A, Setaluri, V, and de la Serna, IL. Modulation of BRAHMA expression by the MAPK/ERK pathway is associated with changes in melanoma proliferation Arch Biochem Biophys. 2014 (563): 125-35
22. Zhao R, Fallon T, **Saladi, SV,** Pardo-Saganta A, Villoria J, Mou H, Vinarsky V, Gonzalez-Celeiro M, Nunna N, Hariri LP, Camargo F, Ellisen LW, Rajagopal J. YAP tunes airway epithelial size and architecture by regulating the identity, maintenance and self-renewal of stem cells. Dev Cell. 2014 (2):151-65.
    - Article previewed in the issue highlighting the significance of the study.
23. Forster N, **Saladi SV**, Bragt MV, Sfondouris ME, Jones FE, Li Z, Ellisen LW. p63 mediated basal cell signaling controls luminal progenitor function and lactation. Dev. Cell. 2014; 28:147-160.
    - Article recommended by Faculty of 1000.
    - Article featured as cover of the issue.
    - Article previewed in the issue highlighting the significance of the study.
24. **Saladi SV,** Wong P, Trivedi A, Marathe H, Keenen B, et al, de la Serna IL. BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. Pigment Cell Melanoma. Pigment Cell & Melanoma Res. 2013; 26(3):377-91
25. Ren G, Feng J, Datar I, Yeung A, **Saladi SV**, Feng Y, de la Serna IL, and Yeung KC. A micro-RNA connection in BRafV600E-mediated premature senescence of human melanocytes. Int J Cell Biol. 2012: **91**,32-42.
26. **Saladi SV,** Keenen B, Marathe HG, Qi H, Chin KV, and de la Serna IL. Modulation of extra-cellular matrix/ adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Mol Cancer. 2010 Oct 22;9 (1):280.
27. **Saladi SV,** Marathe HG and de la serna IL. SWItching on the Transcriptional Circuitry in Melanoma, Epigenetics 2010 Aug 11;5 (6).
28. **Saladi SV,** and de la Serna IL. ATP dependent chromatin remodeling enzymes in embryonic stem cells. Stem Cell Reviews and Reports 2010 Mar; 6 (1): 62-73.
29. Keenen B, Qi H, **Saladi SV**, Yeung M, and de la Serna IL. Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene 2010 29(1): 81-92*.*
30. Viswanathan M, Sangiliyandi G, **Vinod SS,** Mohanprasad BK, Shanmugam G. Genomic instability and tumor-specific alterations in oral squamous cell carcinomas assessed by inter-(simple sequence repeat) PCR. Clin. Cancer Res*.* 2003; **9:**1057-62.
31. Rajendra Kumar P, Singhal PK, **Vinod SS,** Mahalingam S. A non-canonical transferable signal mediates nuclear import of simian immunodeficiency virus Vpx protein. J. Mol. Biol*.* 2003; **331:** 1141-56.

Manuscripts in prep or submitted

1. Park JC, Basak NP, Useche M, Park J, et al, Lin D, Faquin W, Sankaran S, **Saladi SV**. Alterations in PIK3CA confer poorer response to nivolumab in HPV-negative head and neck squamous cancers. (submitted)
2. Waghray A, Monga I, Lin B, Shah V, Slyper M, Giotti B, Xu J, Waldman J, Dionne D, Nguyen LT, Lou W, Cai P, Park E, Muus C, Sun J, Surve MV, Yang LCC, Rozenblatt-Rosen O, Dolerey TM, **Saladi SV**, Tsankov AM, Regev A, Rajagopal J. A deep lung cell atlas reveals cytokine-mediated lineage switching of a rare cell progenitor of the human airway epithelium. (manuscript submitted) (on Biorxiv)
3. Riou R, Chen N, Sadagoppan A, et al, de la Serna IL, Lawrence M, **Saladi SV.** ACTL6A controls an immune program and immune response via EZH2-dependent transcriptional repression in HNSCC. (manuscript in prep)
4. Maitituoheti M[#], Shi A[#], Tang M[#], Ho L, Terranova C, Galani K, Keung EZ, Creasy CA, Chen J, Chen N, Singh AK, Chaudhri A, Anvar NE, Yang J, Sarkar S, Jiang S, Malke J, Haydu L, Burton E, Davies MA, Gershenwald JE, Hwu P, Lazar A, Cheah JH, Soule CK, Levine SS, Bernatchez C, **Saladi SV**, Liu D, Wargo J, Boland GM*, Kellis M* and Rai K*. Enhancer reprogramming in

melanoma immune checkpoint therapy resistance (manuscript revised and submitted to *Nature Communications*) (on Biorxiv)

5. Garett JS, Reinoso VM, Slater RO, Price JD, Gosling KM, Otoo N, Atmosukarto II, Davis DS, Riou R, Emerick KS, Quah BJC, Beverdam A, **Saladi SV**[#] & Thompson BJ[#]. YAP1 drives immune evasion in squamous cell carcinoma (manuscript in prep)
6. Chen N, Ekram A, Bonilla G, Lin B, et al, Wu X, de la Serna IL, Sadreyav R, Fisher D, **Saladi SV.** YAP1 promotes MEK inhibitor resistance and immune cold phenotype in cooperation with BRD4 in melanoma. (manuscript submitted)

(* denotes equal contribution, # denotes co-correspondence).

Presentations (Selected)

Oral Presentations

1. Visiting Professor lecture at University of Wisconsin, Madison, USA. April 4, 2022
   Title of the talk: "Targeting Hippo pathway driven oncogenic (-active) chromatin state in cancers"
2. Invited to give a talk at Department of Cell and Cancer Biology, University of Toledo College of Medicine, Toledo, USA, Oct 28, 2021
   Title of the talk: "Defining the oncogenic chromatin state as a key driver event in squamous cancers"
3. Invited to give a talk at School of Biological Sciences, Madurai Kamaraj University, India, Nov 6, 2020
   Title of the talk: "Defining Transcriptional Reprogramming in Oral Squamous Cancers"
4. Oral presentation at the Mechanisms & Models of Cancer meeting, Cold Spring Harbor Laboratory Aug 11-14, 2020
   Title of the talk: "Deregulated Chromatin Remodeling by Amplified ACTL6A, subunit of SWI/SNF Chromatin Remodeling Complex in Squamous Cancers".
5. Oral presentation at Keystone Symposia: "Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities", Jan 26-30, 2020
   Title of the talk: "Revealing Oncogenic Role of ACTL6A, subunit of SWI/SNF Chromatin Remodeling Complex in Squamous Cancers"
6. Alumni guest lecture at PB. Siddhartha College of Arts and Science, Vijayawada, India, Jan 3, 2020
   Title of the talk: Alumnus lecture to undergrads about career options.
7. Presented at Chabner Colloquium: Answering the Big Questions in Cancer Research, Boston, MA. November 18, 2019
   Title of the talk: "Targeting SWI/SNF/Hippo Axis in Squamous Cancers"
8. Oral presentation at the Mechanisms & Models of Cancer meeting, Salk Institute, Aug 1-4, 2017
   Title of the talk: "Deregulated Chromatin Remodeling and Regenerative Proliferation by ACTL6A, a Novel Oncogene in Squamous Cell Carcinoma"
9. Grand Rounds presentation at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston. June 8, 2017
   Title of talk: "Deregulated Chromatin remodeling as Oncogenic Driver in HNSCC"
10. Special lecture at Ohio State University Cancer Center, Otolaryngology Department, Feb 2, 2017.
    Title of the talk**: "**Deregulated Chromatin Remodeling and Regenerative Proliferation by ACTL6A, a Novel Oncogene in Squamous Cell Carcinoma"
11. Oral presentation at the Mechanisms & Models of Cancer meeting, Salk Institute, Aug 5-8, 2015
    Title of the talk: "Defining Oncogenic Transcriptional Reprogramming in Squamous Cell Carcinoma"

FUNDING

Department of Defense (DOD), Idea Award (2022-2025).
Title: Role of KDM4A as an epigenetic regulator with oncogenic and immunosuppressive features in malignant pleural mesothelioma
Role: PI

1R01CA262874 (A1) at NCI (2024-2029)

Title of application: Mechanisms of APOBEC3A-induced cancer evolution and cancer vulnerability
Role: Co-I

Completed

Adenoid Cystic Carcinoma Research Foundation (ACCRF).
Title: Targeting Hippo pathway in Adenoid Cystic Carcinoma
Role: PI

Melanoma Research Foundation (MRF) Outstanding Young Investigator Team
Title: Characterizing the Role of the Hippo Pathway during Melanoma Immunotherapy
Role: Co-PI

MEEI Startup Funds - MEEI (2018-2023) including Mike Toth Cancer Center Funds (2021-2023)